The technology is ready to start phase 3 testing in GSK’s asthma product Ventolin (salbutamol) next year, and according to the drugmaker has the potential to reduce greenhouse gas emissions from ...

Pharma giant GSK is planning to create a low-emission version of its Ventolin medicine ... which delivers the medicine salbutamol into the lungs, is a key source of emissions.